Welcome to our dedicated page for Arena Pharmaceuticals news (Ticker: ARNA), a resource for investors and traders seeking the latest updates and insights on Arena Pharmaceuticals stock.
This page provides a historical news archive for Arena Pharmaceuticals, Inc. (ARNA), a clinical-stage biopharmaceutical company that focused on developing investigational therapies for immuno-inflammatory and cardiovascular diseases. The news flow around ARNA captured key milestones in its clinical programs, corporate developments, and the definitive agreement under which Pfizer agreed to acquire Arena in an all-cash transaction.
Readers can review company-issued press releases covering progress in Arena’s gastroenterology, dermatology, and cardiology pipelines. These include updates on the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials of etrasimod in ulcerative colitis, the Phase 2/3 CULTIVATE program in Crohn’s disease, and Phase 2 studies of etrasimod in atopic dermatitis and alopecia areata. Additional news items describe Phase 2 development of cardiovascular assets temanogrel and APD418, as well as collaborations and option agreements related to other investigational compounds.
The archive also contains quarterly and annual financial result announcements, which detail Arena’s research and development spending, selling, general and administrative expenses, and net losses as it advanced its clinical-stage portfolio. Corporate governance and compensation-related releases, such as inducement grants under Nasdaq Listing Rule 5635(c)(4), provide further insight into Arena’s growth and hiring during its development phase.
Because Arena entered into an acquisition agreement with Pfizer, these news items primarily serve as historical context for ARNA rather than current standalone company updates. Investors, researchers, and students of the biopharmaceutical sector can use this record to trace how Arena communicated the evolution of its pipeline, its financial profile as a clinical-stage company, and the strategic rationale presented when Pfizer announced its plan to acquire Arena.
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced its Q3 2020 financial results, reporting revenues of $20,000, down from $1.4 million in Q3 2019. The net loss increased to $97.4 million, with a diluted loss per share of $1.69. R&D expenses rose to $79.8 million due to advancing clinical studies. Notably, the ADVISE trial results support a Phase 3 program for etrasimod. Arena also completed enrollment for the CAPTIVATE Phase 2b trial and initiated several new trials in their pipeline. Cash, cash equivalents, and marketable securities stood at $1.2 billion at the end of Q3.
Arena Pharmaceuticals, Inc. reported favorable topline results from its Phase 2b ADVISE clinical trial of etrasimod for moderate-to-severe atopic dermatitis (AD). The trial met key objectives, showcasing significant safety and early efficacy, with one-third of participants achieving clear skin at week 12. However, etrasimod did not meet its primary endpoint for EASI change. A post-hoc analysis revealed that the drug shows a statistically significant effect when accounting for dose interruptions. Arena plans to advance etrasimod to a Phase 3 program based on these findings.
Arena Pharmaceuticals (Nasdaq: ARNA) will announce its Q3 2020 financial results and provide a corporate update on November 9, 2020, after market close. A conference call is scheduled for the same day at 4:30 PM ET, inviting participation from the investment community. Investors can access the call via phone or through a live webcast on Arena's investor relations webpage. This event could be pivotal for understanding the company's financial health and future strategies.
Arena Pharmaceuticals (Nasdaq: ARNA) announced the successful launch of Longboard Pharmaceuticals, following a $56 million financing led by Farallon Capital Management and others. Previously a wholly-owned subsidiary, Longboard aims to develop CNS-targeted assets birthed from Arena's GPCR research. The financing will support clinical and preclinical programs for LP352, LP143, and LP659, focusing on neurological conditions. Arena shareholders will maintain equity value in Longboard and future royalties. Leadership from Arena will join Longboard's board to steer the new venture.
Arena Pharmaceuticals (Nasdaq: ARNA) announced on October 15, 2020, that its Compensation Committee granted inducement stock options and restricted stock units (RSUs) to seven new employees. In total, 66,475 stock options and 11,760 RSUs were granted, with a non-qualified option exercise price set at $81.57 per share. The options will vest over four years, while RSUs will also follow a four-year vesting schedule. This move aims to attract talent and aligns with Nasdaq Listing Rule 5635(c)(4).
Arena Pharmaceuticals (ARNA) announced its participation in the 26th Annual United European Gastroenterology (UEG) Week, scheduled for October 11-13, 2020. The company will present new data from its Phase 2 OASIS trial for etrasimod, focused on ulcerative colitis, along with preclinical data for olorinab, targeting gastrointestinal pain. Key presentations include a symposium on investigational treatments and detailed findings from clinical trials. Both drugs remain investigational and are not approved for use.
Arena Pharmaceuticals (Nasdaq: ARNA) has completed full enrollment of the Phase 2b CAPTIVATE trial for olorinab, targeting abdominal pain in irritable bowel syndrome (IBS). The trial included 273 participants across 70 U.S. sites, focusing on improving the Average Abdominal Pain Scale (AAPS) over 12 weeks. Olorinab, a highly-selective CB2 receptor agonist, aims to provide pain relief with low abuse potential. Topline data is expected in early 2021, marking a significant step in offering a non-opioid treatment option for IBS patients.
Arena Pharmaceuticals (Nasdaq: ARNA) announced on September 15, 2020, that its Compensation Committee granted inducement stock options for 68,825 shares and restricted stock units (RSUs) for 12,420 shares to nine new employees. The stock options have an exercise price of $69.25 per share, matching the closing price on the grant date, and will vest over four years. The RSUs will also vest over the same period, with 25% vesting at the first quarterly date following the one-year anniversary. This move aligns with Nasdaq Listing Rule 5635(c)(4) as an inducement for new hires.
Arena Pharmaceuticals (Nasdaq: ARNA) announced that CEO Amit D. Munshi will present a corporate update at the Jefferies Virtual Next Generation IBD Therapeutics Summit on September 23 at 1:45 PM ET. The live audio webcast will be available on Arena's investor relations website, and a replay will be accessible for 30 days post-event. Arena Pharmaceuticals aims to deliver important medicines to patients, demonstrating a commitment to innovation and stakeholder needs in a dynamic market.
Arena Pharmaceuticals (Nasdaq: ARNA) has commenced the ELEVATE UC 12 Phase 3 trial, marking a significant milestone in the evaluation of etrasimod for treating moderately to severely active ulcerative colitis. This trial is part of the larger ELEVATE UC registrational program, which aims to assess the safety and efficacy of etrasimod, an investigational oral medication. The trial involves approximately 450 sites across over 40 countries and is expected to deliver data by the end of 2021, providing a potential new treatment option for patients in need.